Literature DB >> 2291659

Pharmacokinetics and dose proportionality of cefmetazole in healthy young and elderly volunteers.

M T Borin1, G R Peters, T C Smith.   

Abstract

The pharmacokinetics and dose proportionality of cefmetazole were studied in 24 healthy volunteers (12 young and 12 elderly). Each volunteer received single 0.5-, 1-, and 2-g doses of cefmetazole administered intravenously over 5 min according to a three-way crossover design. Serial plasma and urine samples were collected over a 24-h period following dosing and assayed for cefmetazole by a high-performance liquid chromatography method. Results of the dose proportionality portion of the study indicated that cefmetazole pharmacokinetics are linear and proportional with dose in both age groups. Comparisons of pharmacokinetic parameters between the young and elderly groups indicated that the systemic clearance was significantly lower in elderly than in young volunteers (92.4 versus 112 ml/min). Additionally, creatinine clearance was significantly lower in elderly (74.1 ml/min) than in young (92.9 ml/min) subjects. No significant differences between age groups were observed for volume of distribution, urinary recovery, terminal half-life, nonrenal clearance, or renal clearance, although half-life was slightly prolonged in elderly volunteers relative to that in young volunteers (1.54 versus 1.34 h), and renal clearance was slightly lower in elderly than in young volunteers (83.7 versus 96.1 ml/min). Both systemic and renal clearance were significantly correlated with creatinine clearance. These results indicate that the observed age-related differences in the pharmacokinetics of cefmetazole are most likely due to differences in renal function between the two age groups. The small reduction in cefmetazole elimination in the elderly would not warrant dose adjustment in this population.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2291659      PMCID: PMC171969          DOI: 10.1128/AAC.34.10.1944

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

2.  Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods.

Authors:  R N Jones; A L Barry; P C Fuchs; C Thornsberry
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

3.  A new semisynthetic 7alpha-methoxycephalosporin, CS-1170: 7beta-((cyanomethyl)thio)acetamido)-7alpha-methoxy-3-((1-methyl-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylic acid.

Authors:  H Nakao; H Yanagisawa; B Shimizu; M Kaneko; M Nagano
Journal:  J Antibiot (Tokyo)       Date:  1976-05       Impact factor: 2.649

4.  An on-line, column-switching high-performance liquid chromatographic procedure for the removal of probenecid from human plasma, serum, or urine in the quantitative determination of cefmetazole or cefoxitin.

Authors:  W M Bothwell; K S Cathcart; P A Bombardt
Journal:  J Pharm Biomed Anal       Date:  1989       Impact factor: 3.935

5.  Pharmacokinetics of cefmetazole administered intramuscularly and intravenously to healthy adults.

Authors:  J Rodriguez-Barbero; E L Mariño; A Dominguez-Gil
Journal:  Antimicrob Agents Chemother       Date:  1985-10       Impact factor: 5.191

6.  Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.

Authors:  M Ohkawa; M Orito; T Sugata; M Shimamura; M Sawaki; E Nakashita; K Kuroda; K Sasahara
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

7.  Noncompartmental determination of the steady-state volume of distribution.

Authors:  L Z Benet; R L Galeazzi
Journal:  J Pharm Sci       Date:  1979-08       Impact factor: 3.534

8.  Concentrations of cefmetazole in plasma and tissue resulting from peri-incisional administration before appendectomy.

Authors:  J R Rodríguez; E L Mariño; M J Otero; J R Commes; J Garcia; J M Rodriguez; F Lozano; A Dominguez-Gil; A G Alonso
Journal:  Antimicrob Agents Chemother       Date:  1984-11       Impact factor: 5.191

Review 9.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

10.  Disposition of cefoxitin in the elderly.

Authors:  M J Garcia; A Garcia; M J Nieto; A Dominguez-Gil; G Alonso; L Mellado
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1980-11
View more
  2 in total

Review 1.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

2.  Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer.

Authors:  Atsushi Tomizawa; Takatoshi Nakamura; Toshiaki Komatsu; Hiroshi Inano; Rumiko Kondo; Masahiko Watanabe; Koichiro Atsuda
Journal:  J Pharm Health Care Sci       Date:  2017-01-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.